Cerus Corporation is a biomedical products company that develops and commercializes the INTERCEPT Blood System to enhance blood safety. The proprietary technology reduces blood-borne pathogens in donated blood components intended for transfusion, and includes systems for plasma, platelets, red blood cells, and Cryoprecipitation. Cerus Corporation sells its products through a direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally.